Rein Therapeutics (RNTX) Assets Average (2017 - 2026)
Rein Therapeutics (RNTX) posted quarterly Assets Average of $25.2 million for Q1 2026, down 57.9% year-over-year from $59.9 million in Q1 2025, and down 35.21% quarter-over-quarter from $38.9 million in Q4 2025.
Rein Therapeutics (RNTX) Assets Average (2017 - 2026) Analysis & Trends
Rein Therapeutics (RNTX) has reported Assets Average for 10 consecutive years, with $25.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average fell 57.9% year-over-year to $25.2 million; the TTM figure through Mar 2026 stood at $25.2 million (down 57.9% YoY), while the FY2025 annual figure was $43.2 million, down 48.66% from the prior year.
- Assets Average fell to $25.2 million in Q1 2026 per RNTX's latest filing, from $38.9 million in the prior quarter.
- Across five years, Assets Average topped out at $106.8 million in Q3 2024 and bottomed at $13.4 million in Q3 2023.
- Historically, Assets Average has averaged $51.7 million across 5 years, with a median of $44.4 million in 2022.
- Annual changes were most pronounced in 2023 — Assets Average slumped 57.92% — and 2024, when it jumped 696.69%.
- Rein Therapeutics' Assets Average stood at $24.6 million in 2022, then surged by 141.33% to $59.4 million in 2023, then soared by 40.04% to $83.2 million in 2024, then plunged by 53.21% to $38.9 million in 2025, then sank by 35.21% to $25.2 million in 2026.
- Business Quant data shows RNTX's Assets Average at $25.2 million in Q1 2026, $38.9 million in Q4 2025, and $55.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.24 Bn | 131.39 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 86.01 Bn | 78.02 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 65.61 Bn | 60.42 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.92 Bn | 51.78 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.27 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 27.77 Bn | 9.38 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 19.82 Bn |
| 10 | Rein Therapeutics | 55.02 Mn | 55.02 Mn | - | 46.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 46.13 Mn |
| Mar 31, 2026 | 25.22 Mn |
| Dec 31, 2025 | 38.93 Mn |
| Sep 30, 2025 | 55.59 Mn |
| Jun 30, 2025 | 57.55 Mn |
| Mar 31, 2025 | 59.91 Mn |
| Dec 31, 2024 | 83.20 Mn |
| Sep 30, 2024 | 106.81 Mn |
| Jun 30, 2024 | 104.30 Mn |
| Mar 31, 2024 | 102.60 Mn |
| Dec 31, 2023 | 59.42 Mn |
| Sep 30, 2023 | 13.41 Mn |
| Jun 30, 2023 | 15.57 Mn |
| Mar 31, 2023 | 19.58 Mn |
| Dec 31, 2022 | 24.62 Mn |
| Sep 30, 2022 | 30.50 Mn |
| Jun 30, 2022 | 37.01 Mn |
| Mar 31, 2022 | 44.37 Mn |
| Dec 31, 2021 | 51.62 Mn |
| Sep 30, 2021 | 57.65 Mn |